Thank you
This live web event has ended. Thank you for attending.
Description
This webinar will discuss information on emerging treatments of Cardiac Amyloidosis.
Contributors
-
Mathew S. Maurer, MD
Mathew S. Maurer, MD - Dr. Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr. Maurer is a member of the Advanced Cardiac Care Center at NewYork Presbyterian Hospital – Columbia Campus.
Dr. Maurer received a B.S. in biomedical science as part of the seven-year medical school program at CCNY – The Sophie Davis School of Biomedical Education, where he was awarded the Belle Zeller Scholarship. He received his M.D. degree from Mount Sinai School of Medicine and graduated Alpha Omega Alpha. He completed training in internal medicine and cardiology at NewYork Presbyterian Hospital and was Chief Medical Resident.
Dr. Maurer’s work focuses on evaluating age related changes in cardiovascular physiology in order to elucidate the mechanism that underlie the higher prevalence and incidence of cardiovascular disease in older individuals. He has received funding from the National Institute on Aging and National Heart, Lung and Blood Institute to support his research activities.
He has published over 280 articles including peer reviewed manuscripts, reviews and book chapters. He was co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy. Throughout his career, he has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately afflict older adults.